Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Antisense strategy in hematological malignancies.

¹Department of Hematology, Medical University of Lodz, Poland.

Cytokines, Cellular & Molecular Therapy

|July 2, 1999

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

FOXO1 is a TXN- and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism.

Oncogene·2016

Same author

IL-10 promoter polymorphisms influence susceptibility to aGvHD and are associated with proportions of CD4+FoxP3+ lymphocytes in blood after hematopoietic stem cell transplantation.

Tissue antigens·2014

Same author

Haplotype-specific pattern of association of human major histocompatibility complex with non-Hodgkin's lymphoma outcome.

Tissue antigens·2007

Same author

The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant.

Bone marrow transplantation·2007

Same author

Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2004

Same author

High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group.

Bone marrow transplantation·2002

Antisense strategies offer a novel approach to cancer treatment by selectively targeting oncogenes and tumor suppressor genes. This method shows promise for reducing chemotherapy toxicity and improving outcomes in hematological malignancies.

Area of Science:

Oncology
Molecular Biology
Pharmacology

Background:

Standard chemotherapy exhibits significant systemic toxicity due to its broad cellular targets.
Targeting specific oncogenes and tumor suppressor genes offers a more selective approach to cancer therapy.

Purpose of the Study:

To explore the potential of antisense strategies for selective gene inhibition in cancer.
To review the application of antisense oligonucleotides in oncohematology.

Main Methods:

Utilizing antisense oligonucleotides to reduce the expression of specific target genes.
Initiating clinical trials with antisense oligonucleotides against key oncogenes (e.g., bcl-2, c-myc, bcr-abl, c-myb, p53).

Main Results:

Related Experiment Videos

Antisense technology has proven effective in selectively reducing gene expression in vitro.

Clinical trials are underway for various hematological malignancies using antisense oligonucleotides.

Conclusions:

Antisense strategies represent a promising therapeutic modality with reduced systemic toxicity.
Future developments include novel antisense compounds and combination therapies for hematological cancers.